1. Echinacoside can provide a pronounced protection against GalN/LPS-induced acute liver injury in mice.
2. Echinacoside could improve the hematopoietic function of bone marrow in 5-FU-induced myelosuppression mice.
3. Echinacoside could increase viability of rat pheochromocytoma PC12 cells injured by Aβ and suppress the increase in intracellular reactive oxygen species (ROS) triggered by Aβ.
4. Echinacoside inhibits against 6-OHDA-induced neurotoxicity, the mechanism may be involve in attenuating mitochondrial dysfunction and inflammatory responses by reducing ROS production.
5. Transient treatment with Echinacoside inhibits cytochrome c release and caspase-3 activation caused by ensuing rotenone exposure via activating Trk-extracellular signal-regulated kinase (ERK) pathway in neuronal cells.
6. Echinacoside can trigger cells in the G1 phase to enter the S phase and G2 phase, and can improve ROS degradation, it can protect cells from DNA damage, suggest that echinacoside has potential anti-senescence activity.
7. Echinacoside for 12 weeks can effectively and safely prevent vehicle (OVX)-induced osteoporosis in rats via increasing the osteoprotegerin (OPG)/receptor activator of nuclear factor- κ B ligand (RANKL) ratio.
8. Echinacoside can inhibit hypoxia-induced proliferation of PASMCs, which is associated with of PASMCs and improvement of hypoxia, it may be a potential agent for prevention and treatment of hypoxia-induced .
9. Echinacoside induces apoptotic cancer cell death by inhibiting the nucleotide pool sanitizing enzyme MTH1.